RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Background. Since circulating tumor DNA (ctDNA) offers clear advantages as a minimally invasive method for tumor monitoring compared with tumor tissue, we aimed to evaluate genotyping ctDNA using a next-generation sequencing- (NGS-) based panel to identify the prognostic value of mutation status in...
Saved in:
Main Authors: | Jiannan Yao, Wanchun Zang, Yang Ge, Nathaniel Weygant, Pan Yu, Lei Li, Guanhua Rao, Zhi Jiang, Rui Yan, Linjia He, Yang Yu, Mulan Jin, Gang Cheng, Guangyu An |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2018/4248971 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
by: Brenen P. Swofford, et al.
Published: (2017-01-01) -
A case report of infantile fibrosarcoma with BRAF gene mutation with incomplete intestinal obstruction
by: Fan Zhu, et al.
Published: (2025-01-01) -
Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
by: K. Sahadudheen, et al.
Published: (2016-01-01) -
The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
by: Li-Bo Yang, et al.
Published: (2015-01-01) -
Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
by: Michael Hoffmeister, et al.
Published: (2025-02-01)